Antiangiogenic and Antitumoral Effects Mediated by a Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1)-Targeted DNAzyme

Table 1 DNAzyme target site, arm length, sequences and activity in tube formation assays.

DNAzymes	Target sites	Arms	Sequence (5′ to 3′)^a	Activity^b
DT10	250	9/7	AGCTGACCAGGCTAGCTACAACGAGGTGAGC	+
DT11	353	9/7	CCTTTTAAAGGCTAGCTACAACGATCAGTTC	−
DT12	843	8/9	TCTTTGTAGGCTAGCTACAACGAGTTGCATTT	+
DT13	943	8/5	TATTTGGAGGCTAGCTACAACGAATCTA	−
DT14	1324	7/6	GCCTTCAGGCTAGCTACAACGATTTCAT	+
DT15	1592	7/7	TTGTCTGGGCTAGCTACAACGATGCCCAG	+
DT16	1753	9/9	TGCTCTCAAGGCTAGCTACAACGATCTGTTTCC	−
DT17	1910	6/6	GGCACAGGCTAGCTACAACGACTGTGA	+
DT18	2098	7/5	AGAGTGAGGCTAGCTACAACGAGGAGT	+ +
DT19	2161	7/6	TTCCTGGGGCTAGCTACAACGATCTGCA	+
DT20	2323	9/7	ACCAAGTGAGGCTAGCTACAACGACTGAGGC	−

^aDNAzymes were constructed with either symmetric or asymmetric arms depending on the length of the consensus sequence and free energy; the catalytic core sequence was underlined.
^bThe activity was assessed based on no disruption (−), partial disruption (+) and complete disruption (++) of the tube structures in the Matrigel assay.

ISSN: 1528-3658